Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease

BACKGROUND: Chronic kidney disease (CKD) is a very common long-term condition and powerful risk factor for cardiovascular disease (CVD). Low-dose aspirin is of proven benefit in the secondary prevention of myocardial infarction (MI) and stroke in people with pre-existing CVD. However, in people with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallagher, Hugh, Dumbleton, Jennifer, Maishman, Tom, Whitehead, Amy, Moore, Michael V., Fuat, Ahmet, Fitzmaurice, David, Henderson, Robert A., Lord, Joanne, Griffith, Kathryn E., Stevens, Paul, Taal, Maarten W., Stevenson, Diane, Fraser, Simon D., Lown, Mark, Hawkey, Christopher J., Roderick, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021558/
https://www.ncbi.nlm.nih.gov/pubmed/35449015
http://dx.doi.org/10.1186/s13063-022-06132-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021558/
https://www.ncbi.nlm.nih.gov/pubmed/35449015
http://dx.doi.org/10.1186/s13063-022-06132-z

Ejemplares similares